These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 30464680)
1. Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario. Kim CS; Hannouf MB; Sarma S; Rodrigues GB; Rogan PK; Mahmud SM; Winquist E; Brackstone M; Zaric GS Curr Oncol; 2018 Oct; 25(5):307-316. PubMed ID: 30464680 [TBL] [Abstract][Full Text] [Related]
2. Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada. Kim CS; Hannouf MB; Sarma S; Rodrigues GB; Rogan PK; Mahmud SM; Winquist E; Brackstone M; Zaric GS Acta Oncol; 2015 Nov; 54(10):1781-7. PubMed ID: 25825957 [TBL] [Abstract][Full Text] [Related]
3. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Seve P; Sawyer M; Hanson J; Broussolle C; Dumontet C; Mackey JR Cancer; 2006 May; 106(9):2058-66. PubMed ID: 16583433 [TBL] [Abstract][Full Text] [Related]
4. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Pentheroudakis G; Greco FA; Pavlidis N Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP). Schaffer AL; Pearson SA; Perez-Concha O; Dobbins T; Ward RL; van Leeuwen MT; Rhee JJ; Laaksonen MA; Craigen G; Vajdic CM PLoS One; 2020; 15(3):e0230373. PubMed ID: 32191753 [TBL] [Abstract][Full Text] [Related]
6. Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. Randén M; Rutqvist LE; Johansson H Acta Oncol; 2009; 48(6):915-20. PubMed ID: 19363713 [TBL] [Abstract][Full Text] [Related]
7. The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study. Hannouf MB; Winquist E; Mahmud SM; Brackstone M; Sarma S; Rodrigues G; Rogan PK; Hoch JS; Zaric GS Pharmacoecon Open; 2018 Sep; 2(3):255-270. PubMed ID: 29623630 [TBL] [Abstract][Full Text] [Related]
8. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. Raghav K; Mhadgut H; McQuade JL; Lei X; Ross A; Matamoros A; Wang H; Overman MJ; Varadhachary GR PLoS One; 2016; 11(5):e0154985. PubMed ID: 27171493 [TBL] [Abstract][Full Text] [Related]
9. Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: A population-based nested cohort study in Australian Government Department of Veterans' Affairs clients. Schaffer AL; Pearson SA; Dobbins TA; Er CC; Ward RL; Vajdic CM Cancer Epidemiol; 2015 Aug; 39(4):578-84. PubMed ID: 26100364 [TBL] [Abstract][Full Text] [Related]
10. Differences in experiences of care between patients diagnosed with metastatic cancer of known and unknown primaries: mixed-method findings from the 2013 cancer patient experience survey in England. Wagland R; Bracher M; Drosdowsky A; Richardson A; Symons J; Mileshkin L; Schofield P BMJ Open; 2017 Sep; 7(9):e017881. PubMed ID: 28963312 [TBL] [Abstract][Full Text] [Related]
11. Site-specific survival rates for cancer of unknown primary according to location of metastases. Hemminki K; Riihimäki M; Sundquist K; Hemminki A Int J Cancer; 2013 Jul; 133(1):182-9. PubMed ID: 23233409 [TBL] [Abstract][Full Text] [Related]
12. An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. Vajdic CM; Er CC; Schaffer A; Dobbins T; Wyld L; Meagher NS; Barrett J; Ward RL; Pearson SA Cancer Epidemiol; 2014 Aug; 38(4):460-4. PubMed ID: 24929356 [TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. Jerzak KJ; Berry S; Ko YJ; Earle C; Chan KK Int J Cancer; 2017 May; 140(9):2162-2167. PubMed ID: 28220486 [TBL] [Abstract][Full Text] [Related]
14. [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration]. Begum N; Hubold C; Buchmann I; Thorns C; Bouchard R; Lubienski A; Schlöricke E; Zimmermann M; Lehnert H; Bruch HP; Bürk CG Zentralbl Chir; 2014 Jun; 139(3):284-91. PubMed ID: 23508839 [TBL] [Abstract][Full Text] [Related]
15. Health-related predictors of cancer registry-notified cancer of unknown primary site (CUP). Vajdic CM; Perez-Concha O; Rhee JJ; Dobbins T; Ward RL; Schaffer AL; van Leeuwen MT; Laaksonen MA; Craigen G; Pearson SA Cancer Epidemiol; 2019 Aug; 61():1-7. PubMed ID: 31082704 [TBL] [Abstract][Full Text] [Related]
16. Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP). Vajdic CM; Perez-Concha O; Dobbins T; Ward RL; Schaffer AL; van Leeuwen MT; Rhee JJ; Laaksonen MA; Craigen G; Pearson SA Cancer Epidemiol; 2019 Jun; 60():156-161. PubMed ID: 31015097 [TBL] [Abstract][Full Text] [Related]
17. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated? Sacher AG; Le LW; Lau A; Earle CC; Leighl NB Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153 [TBL] [Abstract][Full Text] [Related]
18. Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010. Brewster DH; Lang J; Bhatti LA; Thomson CS; Oien KA Cancer Epidemiol; 2014 Jun; 38(3):227-34. PubMed ID: 24726751 [TBL] [Abstract][Full Text] [Related]
19. Patient characteristics associated with definitive diagnosis of metastatic pancreatic cancer in those initially diagnosed with cancer of unknown primary. Lee White L; Smith-Gagen J; Elliott L; Lu M Mol Clin Oncol; 2023 Dec; 19(6):101. PubMed ID: 38022848 [TBL] [Abstract][Full Text] [Related]
20. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]